Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,499	180 Pages	Expert Market Research	February, 2024	EMAR18558290

Best Price Guarantee
Price	from $5,499
Length	180 Pages
Publisher	Expert Market Research
Published Date	February, 2024
SKU	EMAR18558290

Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032

Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032

Hepatic Encephalopathy Treatment Market Outlook

The hepatic encephalopathy treatment market size was valued at USD 1.65 billion in 2023, driven by increasing incidence of liver cirrhosis across the major markets. The market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to achieve a value of USD 2.68 billion by 2032.

Hepatic Encephalopathy: Introduction

Hepatic encephalopathy is a neurological disorder stemming from liver dysfunction, often due to chronic liver disease like cirrhosis. It disrupts the brain's function, leading to a spectrum of symptoms ranging from mild cognitive impairments to deep coma. The condition arises when the liver fails to remove toxins from the blood, allowing substances like ammonia to accumulate and harm brain cells. Management involves treating the underlying liver condition and reducing blood toxin levels.

Key Trends in the Hepatic Encephalopathy Treatment Market

The hepatic encephalopathy (HE) treatment market is influenced by various factors, with key trends shaping its landscape. Enhanced diagnostic tools enable early and more accurate detection of HE. Technologies like blood ammonia level detection, MRI, and CT scans are becoming more sophisticated, aiding in the timely treatment of the condition. The global increase in liver diseases, including cirrhosis and hepatitis, is leading to a higher incidence of hepatic encephalopathy. This trend is driving demand for effective HE treatment options.

Pharmaceutical and biotech companies are investing in R&D to develop novel therapeutics for HE. There's a focus on creating treatments that are more effective, have fewer side effects, and offer easier administration. There's a growing awareness about liver health and HE among the general population. This, coupled with increased healthcare spending in many countries, is leading to better access to treatment options.

Treatment of HE is evolving from traditional methods to more comprehensive, multimodal strategies. This includes the use of dietary management, medications, and in severe cases, liver transplantation. There's a growing interest in using probiotics and other non-pharmacological treatments to manage HE. These methods are being researched for their potential to improve gut health and reduce the production of toxins that can contribute to HE.

Advances in genomics and bioinformatics are paving the way for personalized treatment approaches. Predictive analytics are being used to understand patient risk profiles and tailor treatments accordingly.

Regulatory bodies are providing support for HE treatment development through fast-track designations, funding for research, and guidance on clinical trial designs. This is encouraging innovation and speeding up the process of bringing new treatments to the market.

Hepatic Encephalopathy Treatment Market Segmentation

Market Breakup by Drug Class

Antibiotics
Laxatives
L-ornithine
L-aspartate
Others

Market Breakup by Diagnosis

Blood Tests
CT Scan
Liver Functioning Tests (LFT)
Others

Market Breakup by Treatment

Medication
Surgery
Others

Market Breakup by Route of Administration

Oral
Injectable
Intravenous
Rectal
Others

Market Breakup by End User

Hospitals
Homecare
Speciality Clinics
Others

Market Breakup by Distribution Channels

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Market Breakup by Region

United States
EU-4 and the United Kingdom
Germany
France
Italy
Spain
United Kingdom
Japan

Hepatic Encephalopathy Treatment Market Overview

North America shows a comprehensive approach to treatment, with advanced healthcare facilities and widespread use of medications like lactulose and rifaximin. The U.S. leads in adopting new therapies and investing in liver disease research.Europe, characterized by strong healthcare systems and a focus on evidence-based treatments. Countries like Germany, the UK, and France actively integrate dietary management and pharmacotherapy in Hepatic Encephalopathy treatment protocols.

Japan is experiencing rapid growth due to increasing liver disease prevalence. The region is embracing both traditional and modern treatment approaches, with growing healthcare investments improving access to advanced therapies.

Hepatic Encephalopathy Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Salix Pharmaceuticals
Mallinckrodt plc.
Merck & Co., Inc.
Bausch Health
Takeda Pharmaceutical Company Limited
Johnson & Johnson Services, Inc.
Eisai Co., Ltd
AbbVie Inc.
Hikma Pharmaceuticals PLC
Vedanta Biosciences
Patricia Bloom
Umecrine Cognition
Axcella Health Inc.
Pfizer Inc.
Rebiotix

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

1 Preface: 1.1 Objectives of the Study; 1.2 Key Assumptions; 1.3 Report Coverage – Key Segmentation and Scope; 1.4 Research Methodology
2 Executive Summary
3 Hepatic Encephalopathy Treatment Overview: 3.1 Guidelines and Stages; 3.2 Pathophysiology; 3.3 Screening and Diagnosis; 3.4 Treatment Pathway
4 Patient Profile: 4.1 Patient Profile Overview; 4.2 Patient Psychology and Emotional Impact Factors; 4.3 Risk Assessment and Treatment Success Rate
5 Hepatic Encephalopathy Epidemiology Analysis – 7MM: 5.1 7MM Epidemiology Scenario Overview (2017-2032); 5.2 United States Hepatic Encephalopathy Epidemiology Forecast (2017-2032); 5.3 EU-4 and United Kingdom Hepatic Encephalopathy Epidemiology Forecast (2017-2032); 5.3.1 Germany Hepatic Encephalopathy Epidemiology Forecast (2017-2032); 5.3.2 France Hepatic Encephalopathy Epidemiology Forecast (2017-2032); 5.3.3 Italy Hepatic Encephalopathy Epidemiology Forecast (2017-2032); 5.3.4 Spain Hepatic Encephalopathy Epidemiology Forecast (2017-2032); 5.3.5 United Kingdom Hepatic Encephalopathy Epidemiology Forecast (2017-2032); 5.4 Japan Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
6 Hepatic Encephalopathy Treatment Market Overview – 7MM: 6.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023); 6.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
7 Hepatic Encephalopathy Treatment Market Landscape – 7MM: 7.1 Amyotrophic Lateral Sclerosis: Developers Landscape; 7.1.1 Analysis by Year of Establishment; 7.1.2 Analysis by Company Size; 7.1.3 Analysis by Region; 7.2 Hepatic Encephalopathy Treatment Product Landscape; 7.2.1 Analysis by Drug Class; 7.2.2 Analysis by Treatment; 7.2.3 Analysis by Route of Administration
8 Hepatic Encephalopathy Treatment Challenges and Unmet Needs: 8.1 Treatment Pathway Challenges; 8.2 Compliance and Drop-Out Analysis; 8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Hepatic Encephalopathy Treatment Market Dynamics: 10.1 Market Drivers and Constraints; 10.2 SWOT Analysis; 10.3 Porter’s Five Forces Model; 10.4 Key Demand Indicators; 10.5 Key Price Indicators; 10.6 Industry Events, Initiatives, and Trends; 10.7 Value Chain Analysis
11 Hepatic Encephalopathy Treatment Market Segmentation – 7MM: 11.1 Hepatic Encephalopathy Treatment Market by Drug Class; 11.1.1 Market Overview; 11.1.2 Antibiotics; 11.1.3 Laxatives; 11.1.4 L-ornithine; 11.1.5 L-aspartate; 11.1.6 Others; 11.2 Hepatic Encephalopathy Treatment Market by Diagnosis; 11.2.1 Market Overview; 11.2.2 Blood Tests; 11.2.3 CT Scan; 11.2.4 Liver Functioning Tests (LFT); 11.2.5 Others; 11.3 Hepatic Encephalopathy Treatment Market by Treatment; 11.3.1 Market Overview; 11.3.2 Medication; 11.3.3 Surgery; 11.3.4 Others; 11.4 Hepatic Encephalopathy Treatment Market by Route of Administration; 11.4.1 Market Overview; 11.4.2 Oral; 11.4.3 Injectable; 11.4.4 Intravenous; 11.4.5 Rectal; 11.4.6 Others; 11.5 Hepatic Encephalopathy Treatment Market by End User; 11.5.1 Market Overview; 11.5.2 Hospitals; 11.5.3 Homecare; 11.5.4 Speciality Clinics; 11.5.5 Others; 11.6 Hepatic Encephalopathy Treatment Market by Distribution Channels; 11.6.1 Market Overview; 11.6.2 Hospital Pharmacy; 11.6.3 Retail Pharmacy; 11.6.4 Online Pharmacy; 11.6.5 Others; 11.7 Hepatic Encephalopathy Treatment Market by Region; 11.7.1 Market Overview; 11.7.2 United States; 11.7.3 EU-4 and the United Kingdom; 11.7.3.1 Germany; 11.7.3.2 France; 11.7.3.3 Italy; 11.7.3.4 Spain; 11.7.3.5 United Kingdom; 11.7.4 Japan
12 United States Hepatic Encephalopathy Treatment Market: 12.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023); 12.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032); 12.3 Hepatic Encephalopathy Treatment Market by Drug Class; 12.4 Hepatic Encephalopathy Treatment Market by Treatment
13 EU-4 and United Kingdom Hepatic Encephalopathy Treatment Market: 13.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023); 13.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032); 13.3 Germany Hepatic Encephalopathy Treatment Market Overview; 13.3.1 Hepatic Encephalopathy Treatment Market by Drug Class; 13.3.2 Hepatic Encephalopathy Treatment Market by Treatment; 13.4 France Hepatic Encephalopathy Treatment Market Overview; 13.4.1 Hepatic Encephalopathy Treatment Market by Drug Class; 13.4.2 Hepatic Encephalopathy Treatment Market by Treatment; 13.5 Italy Hepatic Encephalopathy Treatment Market Overview; 13.5.1 Hepatic Encephalopathy Treatment Market by Drug Class; 13.5.2 Hepatic Encephalopathy Treatment Market by Treatment; 13.6 Spain Hepatic Encephalopathy Treatment Market Overview; 13.6.1 Hepatic Encephalopathy Treatment Market by Drug Class; 13.6.2 Hepatic Encephalopathy Treatment Market by Treatment; 13.7 United Kingdom Hepatic Encephalopathy Treatment Market Overview; 13.7.1 Hepatic Encephalopathy Treatment Market by Drug Class; 13.7.2 Hepatic Encephalopathy Treatment Market by Treatment
14 Japan Hepatic Encephalopathy Treatment Market: 14.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023); 14.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032); 14.3 Hepatic Encephalopathy Treatment Market by Drug Class; 14.4 Hepatic Encephalopathy Treatment Market by Treatment
15 Regulatory Framework: 15.1 Regulatory Overview; 15.1.1 US FDA; 15.1.2 EU EMA; 15.1.3 JAPAN PMDA
16 Patent Analysis: 16.1 Analysis by Type of Patent; 16.2 Analysis by Publication year; 16.3 Analysis by Issuing Authority; 16.4 Analysis by Patent Age; 16.5 Analysis by CPC Analysis; 16.6 Analysis by Patent Valuation; 16.7 Analysis by Key Players
17 Grants Analysis: 17.1 Analysis by year; 17.2 Analysis by Amount Awarded; 17.3 Analysis by Issuing Authority; 17.4 Analysis by Grant Application; 17.5 Analysis by Funding Institute; 17.6 Analysis by NIH Departments; 17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis: 18.1 Analysis by Trial Registration Year; 18.2 Analysis by Trial Status; 18.3 Analysis by Trial Phase; 18.4 Analysis by Therapeutic Area; 18.5 Analysis by Geography
19 Funding and Investment Analysis: 19.1 Analysis by Funding Instances; 19.2 Analysis by Type of Funding; 19.3 Analysis by Funding Amount; 19.4 Analysis by Leading Players; 19.5 Analysis by Leading Investors; 19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis: 20.1 Analysis by Partnership Instances; 20.2 Analysis by Type of Partnership; 20.3 Analysis by Leading Players; 20.4 Analysis by Geography
21 Supplier Landscape: 21.1 Salix Pharmaceuticals; 21.1.1 Financial Analysis; 21.1.2 Product Portfolio; 21.1.3 Demographic Reach and Achievements; 21.1.4 Mergers and Acquisitions; 21.1.5 Certifications; 21.2 Mallinckrodt plc.; 21.2.1 Financial Analysis; 21.2.2 Product Portfolio; 21.2.3 Demographic Reach and Achievements; 21.2.4 Mergers and Acquisitions; 21.2.5 Certifications; 21.3 Merck & Co., Inc.; 21.3.1 Financial Analysis; 21.3.2 Product Portfolio; 21.3.3 Demographic Reach and Achievements; 21.3.4 Mergers and Acquisitions; 21.3.5 Certifications; 21.4 Bausch Health; 21.4.1 Financial Analysis; 21.4.2 Product Portfolio; 21.4.3 Demographic Reach and Achievements; 21.4.4 Mergers and Acquisitions; 21.4.5 Certifications; 21.5 Takeda Pharmaceutical Company Limited; 21.5.1 Financial Analysis; 21.5.2 Product Portfolio; 21.5.3 Demographic Reach and Achievements; 21.5.4 Mergers and Acquisitions; 21.5.5 Certifications; 21.6 Johnson & Johnson Services, Inc.; 21.6.1 Financial Analysis; 21.6.2 Product Portfolio; 21.6.3 Demographic Reach and Achievements; 21.6.4 Mergers and Acquisitions; 21.6.5 Certifications; 21.7 Eisai Co., Ltd; 21.7.1 Financial Analysis; 21.7.2 Product Portfolio; 21.7.3 Demographic Reach and Achievements; 21.7.4 Mergers and Acquisitions; 21.7.5 Certifications; 21.8 AbbVie Inc.; 21.8.1 Financial Analysis; 21.8.2 Product Portfolio; 21.8.3 Demographic Reach and Achievements; 21.8.4 Mergers and Acquisitions; 21.8.5 Certifications; 21.9 Hikma Pharmaceuticals PLC; 21.9.1 Financial Analysis; 21.9.2 Product Portfolio; 21.9.3 Demographic Reach and Achievements; 21.9.4 Mergers and Acquisitions; 21.9.5 Certifications; 21.10 Vedanta Biosciences; 21.10.1 Financial Analysis; 21.10.2 Product Portfolio; 21.10.3 Demographic Reach and Achievements; 21.10.4 Mergers and Acquisitions; 21.10.5 Certifications; 21.11 Patricia Bloom; 21.11.1 Financial Analysis; 21.11.2 Product Portfolio; 21.11.3 Demographic Reach and Achievements; 21.11.4 Mergers and Acquisitions; 21.11.5 Certifications; 21.12 Umecrine Cognition; 21.12.1 Financial Analysis; 21.12.2 Product Portfolio; 21.12.3 Demographic Reach and Achievements; 21.12.4 Mergers and Acquisitions; 21.12.5 Certifications; 21.13 Axcella Health Inc.; 21.13.1 Financial Analysis; 21.13.2 Product Portfolio; 21.13.3 Demographic Reach and Achievements; 21.13.4 Mergers and Acquisitions; 21.13.5 Certifictions; 21.14 Pfizer Inc.; 21.14.1 Financial Analysis; 21.14.2 Product Portfolio; 21.14.3 Demographic Reach and Achievements; 21.14.4 Mergers and Acquisitions; 21.14.5 Certifications; 21.15 Rebiotix; 21.15.1 Financial Analysis; 21.15.2 Product Portfolio; 21.15.3 Demographic Reach and Achievements; 21.15.4 Mergers and Acquisitions; 21.15.5 Certifications
22 Hepatic Encephalopathy Treatment Market- Distribution Model (Additional Insight): 22.1 Overview; 22.2 Potential Distributors; 22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight): 24.1 Very Small Companies; 24.2 Small Companies; 24.3 Mid-Sized Companies; 24.4 Large Companies; 24.5 Very Large Companies
25 Payment Methods (Additional Insight): 25.1 Government Funded; 25.2 Private Insurance; 25.3 Out-of-Pocket; *Additional insights provided are customisable as per client requirements.